At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Posaconazole 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study on Treatment of Refractory Fungal Infections With Posaconazole. The "TIP" Study.
In Brief
A Phase 2 clinical trial evaluating Posaconazole for Mycoses. Completed, enrolled 40 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of posaconazole in the early treatment of fungal infections in participants who are refractory to, intolerant to, or medically precluded from first-line monotherapy or first-line combination antifungal therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMycoses
Countries--
CollaboratorsJSS Medical Research Inc.
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartDec 2007
Primary CompletionNov 2012
TodayJul 2026
First PostedOct 30, 2007
Enrollment StartDec 1, 2007
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.7 years ago
Interventions
Posaconazoledrug
Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.